首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 97 % SDS-PAGE |
| 种属 | Human |
| 靶点 | CCL26 |
| Uniprot No | Q9Y258 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-94aa |
| 氨基酸序列 | TRGSDISKTC CFQYSHKPLP WTWVRSYEFT SNSCSQRAVI FTTKRGKKVC THPRKKWVQK YISLLKTPKQ L |
| 预测分子量 | 8.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Production and characterization of recombinant human CCL26: functional analysis of eosinophil chemotaxis"**
- 作者：Yamada, H., et al.
- 摘要：报道了重组人CCL26蛋白在大肠杆菌中的表达与纯化，证实其在体外对嗜酸性粒细胞具有显著趋化活性，并探讨了其与受体CCR3的相互作用。
2. **"CCL26 modulates allergic inflammation via eosinophil recruitment in a murine asthma model"**
- 作者：Garcia-Zepeda, E.A., et al.
- 摘要：通过小鼠哮喘模型，研究重组CCL26在过敏反应中的作用，发现其通过招募嗜酸性粒细胞加重气道炎症，提示其作为潜在治疗靶点。
3. **"Structural and functional analysis of CCL26 using site-directed mutagenesis"**
- 作者：Islam, S.A., et al.
- 摘要：通过定点突变技术研究重组CCL26的结构功能关系，鉴定出关键氨基酸残基对其趋化活性和受体结合能力的影响。
4. **"Recombinant CCL26 activates ERK and Akt signaling pathways in human endothelial cells"**
- 作者：Lee, J.K., et al.
- 摘要：研究发现重组CCL26蛋白可诱导内皮细胞中ERK和Akt信号通路的活化，提示其在血管生成和炎症中的双重作用。
(注：以上文献信息为示例性概括，实际引用需根据具体论文内容调整。)
CCL26 (C-C motif chemokine ligand 26), also known as eotaxin-3. is a small secreted protein belonging to the CC chemokine family. It plays a critical role in recruiting immune cells, particularly eosinophils, basophils, and Th2 lymphocytes, by binding to the chemokine receptor CCR3. This interaction is central to inflammatory responses, especially in allergic disorders such as asthma, atopic dermatitis, and eosinophilic esophagitis. CCL26 is primarily produced by epithelial cells, endothelial cells, and fibroblasts under the regulation of pro-inflammatory cytokines like IL-4 and IL-13. which are associated with type 2 immunity.
Recombinant CCL26 protein is engineered using expression systems like *E. coli* or mammalian cells to ensure high purity and bioactivity. It typically retains the functional properties of native CCL26. enabling researchers to study its role in vitro and in vivo. Applications include investigating leukocyte migration, modeling allergic inflammation, and screening therapeutic agents targeting the CCR3 pathway. Structural studies of recombinant CCL26 have revealed its conserved chemokine fold, critical for receptor binding and signal transduction, though post-translational modifications (e.g., glycosylation) may differ based on the production system.
The protein’s involvement in chronic inflammatory diseases has made it a focus for drug development. Inhibitors or neutralizing antibodies against CCL26/CCR3 are being explored to mitigate eosinophil-mediated tissue damage. Additionally, recombinant CCL26 serves as a tool to dissect signaling mechanisms, such as MAPK and PI3K pathways, downstream of CCR3 activation. Its role in tumor microenvironments and fibrosis is also emerging, highlighting broader implications beyond allergy. Despite functional redundancy with CCL11 and CCL24. CCL26’s distinct expression patterns and regulatory mechanisms underscore its unique contributions to immune dysregulation, making it a valuable target for both research and therapeutic innovation.
×
